TargetBeta
ROCK2
Rho associated coiled-coil containing protein kinase 2 · Pleckstrin homology domain containing
3 programs in company-led studies act on ROCK2, from 3 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 266 running | ROCK1 | NCIt |
| netarsudilrule | Alcon | phase 4 | 200 running | ROCK1 | ChEMBL |
| TDI01 | Sino Biopharmaceutical | phase 3 | 33 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Bronchiolitis Obliterans Syndrome, 2 programs
- Autoimmune Diseases, 1 program
- Corneal Edema, 1 program
- Fuchs' Endothelial Dystrophy, 1 program
- Glaucoma, 1 program
- Glaucoma, Open-Angle, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Immune System Diseases, 1 program
- Psoriasis, 1 program
- Scleroderma, Diffuse, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 26, 2027belumosudil · Sanofi · phase 4 · NCT07726914
- Jul 30, 2029TDI01 · Sino Biopharmaceutical · phase 3 · NCT07464912
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.